Q-omics provides the consensus-scored SC5D profile across patient tissues and cancer cell-line models. SC5D expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SC5D is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SC5D RNA expression shows 20,164 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where SC5D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SC5D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SC5D survival associations across molecular data types. SC5D RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SC5D RNA expression–survival associations across cancer types. High SC5D expression shows unfavorable associations in HNSC, UVM, CESC and KIRP, but favorable associations in KIRC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SC5D RNA expression.
This table summarizes SC5D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SC5D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SC5D shows lower tumor expression in KIRC, BRCA and CHOL and higher tumor expression in HNSC, KICH and COAD. The KIRC box plot shows higher SC5D RNA expression in normal versus tumor tissue (log2 FC = −0.928, t-test p < 0.001).
This table shows molecular features associated with SC5D in patient tissues and cancer cell lines. In patient samples, SC5D shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SC5D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
